Business
Easton Pharmaceuticals and Partner BMV Medica Announces Regulatory Filing of Its Patented Women's Health Diagnostic Product, VS-Sense for the Mexico Market, Provides Update on Generic Cancer Drugs, Paclitaxel, Docetaxel
Easton Pharmaceuticals and Partner BMV Medica Announces Regulatory Filing of Its Patented Women's Health Diagnostic Product, VS-Sense for the Mexico Market, Provides Update on Generic Cancer Drugs, Paclitaxel, Docetaxel.
About this update from Easton Pharmaceuticals Inc
[{"type":"text","content":"\n \n \n Easton Pharmaceuticals and Partner BMV Medica Announces Regulatory Filing of Its Patented Women's Health Diagnostic Product, VS-Sense for the Mexico Market, Provides Update on Generic Cancer Drugs, Paclitaxel, Docetaxel\n \n \nEaston Pharmaceuticals and Partner BMV Medica Announces Regulatory Filing of Its Patented Women's Health Diagnostic Product, VS-Sense for the Mexico Market, Provides Update on Generic Cancer Drugs, Paclitaxel, Docetaxel\n \n TORONTO, ON--(Marketwired - Feb 16, 2016) - Easton Pharmaceuticals Inc. (OTC PINK: EAPH), together with their commercial alliance partner Ackerman Pharma, announces filing of patented, point-of-care, VS-Sense Diagnostic test through \"fast-track\" third-party authorized reviewer DefiLatina Healthcare, S.A. de C.V. for regulatory approval in Mexico, provides update on generic cancer drugs Paclitaxel and Docetaxel initiatives.\n Over the next few weeks Defi Latina -- one of only a few authorized third-party reviewers licensed by the Ministry of Health in Mexico to review and pre-approve Regulatory dossiers prior to submission -- is undergoing a detailed review of the regulatory dossier for VS-Sense, a unique point-of-care vaginal discharge diagnostic test called VagiSan in Mexico. The \"fast-track\" review process through authorized third-party reviewers can speed up approval times from several years to a few short months if the regulatory dossier is complete. Easton / BMV have worked diligently over recent months with the manufacturer CommonSense LTD of Israel, to ensure a complete dossier is in place, and expects approval to be granted before the planned launch date of April 2016.\n Prior to the VS Sense Diagnostic test regulatory filing submission, Easton / BMV Medica announced a first-order of the CommonSense products with the total number of units ordered at 230,000 -- 90,000 of the VS-Sense and 140,000 of the AmnioSense, enough product for launch and three - six months of sales. The AmnioSense diagnostic test as well as the Gynofit bacterial vaginosis treatment are already approved in Mexico through third-party consultants. Easton's partner, BMV Medica is in the process of having the Marketing Approvals (registrations) transferred to BMV, so all three products can be launched at the same time. Easton / BMV will be placing an initial order for Gynofit with the Swiss manufac...